139 results about "Rat liver" patented technology

The present invention relates to an anti-free radical oxidation, liver-protective, senile dementia preventing and anti-aging active dehydrogenation silybin double-ester derivative and the related medicinal salt or solvent compound. The invention also relates to the preparation method for the compound on the formula 1, as well as the related medication compounds and the curatorial uses. The compound of the invention can protect the liver cells of a rat liver cell injury in vitro model, which can be expected to prevent liver damage in drug use; the compound of the invention is provided with the biological activities of in vitro removing superoxide anion free radicals and diphenyl-benzyl-hydrazine free radicals, and restraining generation of grease peroxide induced by free radicals. The compound can strongly confront the PC12 cells damage caused by free radicals, which can be expected to prevent various diseases caused by free radicals in drug use.

The invention relates to a rat liver cancer model with different liver matrix hardness backgrounds and a preparation method of the rat liver cancer model. The method for preparing the rat liver cancer model with different liver matrix backgrounds is characterized by specifically comprising the following steps of: after grouping the rats, injecting pure carbon tetrachloride to an abdominal region in a hypodermic manner; injecting a carbon tetrachloride-olive oil solution to the abdominal region in the hypodermic manner; detecting through a texture analyzer to form the rat model with different liver matrix hardness; taking liver cancer cells which are in-vitro cultured and grown well and injecting the liver cancer cells to the rat to form hypodermic liver cancer cells; in-situ planting the formed liver cancer tumor source to the rat model with different liver matrix hardness to obtain the rat liver cancer model with different liver matrix hardness backgrounds. The rat liver cancer model with different liver matrix hardness backgrounds can be used for well displaying liver cancer malignant pathological characteristics under the liver matrix hardness interference, simulating and reproducing pathological characteristics of clinical liver matrix hardening background liver cancer and solving the problems that an ideal experiment system, an animal model and the like are lacked in reaching the development of the liver cancer due to the liver matrix hardness changes.

The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in treated rat liver and in human liver and which may be used in their entirety or in part to diagnose, stage, or treat a liver disorder, to monitor diagnostic and therapeutic applications, to detect metabolic and toxicological responses, and to elucidate drug mechanism of action.

The invention discloses a method for inducing a rat liver cancer model by injecting diethyl nitrosamine DEN in coordination with microcystin MC-LR into a rat body through intraperitoneal injection. Indexes such as liver weight to body weight ratio, liver appearance, liver histopathological slicing and GST-Pi (Glutathione S-transferase) protein expression level clearly show liver cell injury phase, liver cell hyperplasia-hepatocirrhosis phase and liver cell carcinomatous change process in a rat liver cancer occurring process, and find that the liver cancer model induced by the DEN in coordination with the microcystin MC-LR has a more obvious effect at the same time than that induced by DEN independently; the tumor formation time is shorter; and the model is an ideal model for researching occurrence of the liver cancer of a human body. The model has the characteristic of clearly showing each stage for occurrence of the liver cancer and contributing to research of a liver cancer occurrence process mechanism, detection of precancerous lesion and development of treatment medicaments.

The invention pertains to the field of biomedical technology, in particular to an orthotopic transplanted mouse liver cancer model which takes the research of the occurrence and development mechanisms of liver cancer and the development of anti-tumor drugs as the purposes, and the preparation method and the application thereof. The H22 cell strain of stable transfection EGFP is injected into the BALB/c mouse peritoneal cavity for amplification; the ascites is extracted from the H22 ascites cancer mouse peritoneal cavity, then cell separation is carried out and cell suspension is prepared; the mouse peritoneal cavity is opened, and the cell suspension is extracted by a micro-syringe to be injected into the mouse liver; a cotton bud with 75 percent alcohol is pressed on the needle hole till the surface of the liver does not bleed any more, and the needle hole is sealed by bonding agent; then the liver surface is washed by physiological saline, and layer separation is carried out and the peritoneal cavity is closed. The results show that the occurrence rate of mouse liver cancer is 100 percent and the natural remission rate is zero. The model is an ideal orthotopic liver cancer model which can be used in the research of the development and metastasis mechanisms of orthotopic liver cancer and can also be applicable to the development of anti-tumor drugs, the experimental treatment and diagnosis research of liver cancer.

Surfaces useful for cell culture comprise a support to which is bound a CAR material, and, bound to the CAR material, collagen VI or a biologically active fragment or variant thereof and, optionally, one or more other ECM proteins (or fragments or variants thereof) such as elastin, fibronectin, vitronectin, tenascin, laminin, entactin, aggrecan, decorin, collagen I, collagen III, and collagen IV. Also, optionally present on the surface is one or more polycationic polymers, such as poly-D-lysine or poly-D-ornithine. This surface is used in cell culture to promote cell attachment, survival, and/or proliferation of a number of different cell types such as (a) liver cells (e.g., HepG2 tumor cells, and a newly discovered line of rat liver epithelial stem cells) (b) osteoblasts, such as the murine cell line MC3T3 cell line and (c) primary bone marrow cells. Kits comprising the surfaces and additional reagents are also disclosed.

The invention provides a method for separating rat hepatocytes. The method comprises the following steps: (a) taking rat liver out; (b) perfusing the liver with calcium-free perfusate pre-heated to 35-38 DEG C until the liver is swollen; (c) cutting infrahepatic vena cava so that the blood flows until the liver becomes earthy yellow; (d) perfusing the liver with calcium-containing perfusate pre-heated to 35-38 DEG C for 3-7 minutes and (e) perfusing the liver with perfusate pre-heated to 35-38 DEG C and containing 0.05% IV-type collagenase for 1-3 minutes. The method for separating rat hepatocytes provided by the invention has the advantages of being simple in operation, small in usage amount of collagenase and high in hepatocyte yield and survival rate.

The invention belongs to the field of pharmaceuticals and relates to application of a cyclocarya paliurus effective part in preparation of health products and medicines which are used for treating a non-alcoholic fatty liver disease. The cyclocarya paliurus effective part mainly contains natural triterpenoid and can be used for effectively reducing rat liver lipid accumulation degree and triglyceride level which are caused by high fat diet, improving the liver histology and liver functions and improving the liver oxidative stress and the organism inflammatory level, so that the cyclocarya paliurus effective part can be used for obviously alleviating non-alcoholic fatty liver disease and preparing health products and medicines which are used for treating the non-alcohol fatty liver disease. The application of the cyclocarya paliurus effective part has the advantage that application range of cyclocarya paliurus preparation in the medical field.

The invention belongs to the field of traditional Chinese medicines and relates to a traditional Chinese compound medicament. The traditional Chinese compound medicament disclosed by the invention is prepared from atractylodes macrocephalaon polysaccharide, jasminoidin and chlorogenic acid in weight ratio of (100-500):(10-150):(1-50). The traditional Chinese compound medicament is produced into oral solid preparations such as granules, tablets and capsules by using a conventional method. Through a high fat die-induced rat fatty liver model experiment, screening applying uniform design and repeated verification, the results show that the traditional Chinese compound medicament has the efficacies that the content of triglyceride of a rat liver tissue in the model can be remarkably reduced, the liver fatty degeneration degree and liver damage are alleviated and no remarkable effect is achieved by a single component; and the compound medicament can be used for preparing medicaments for preventing and controlling simple fatty liver and fatty hepatitis or can be used for preparing medicaments for preventing and controlling the fatty liver diseases.

The invention relates to a preparation method of Beauveria sp. extract with functiosn of a tyrosinase inhibitor and an antioxidant. The preparation method comprises the following operation steps: 1. selecting and culturing Beauveria sp. Strain; and 2. extracting and refining active components from a fermented product, wherein the refining process comprises primary refining and chromatographic refining. The Beauveria sp. and Beauveria sp. extract provided by the invention have tyrosinase inhibiting and antioxidation active effects, and the refined product has the minimum IC50 (50% inhibiting concentration) of 134.5 mu g/ml to tyrosinase and the minimum IC50 of 87.2 mu g/ml to rat liver cell lipid oxidation; the Beauveria sp. extract can be used as articles for daily use to take into effects of whitening, antioxidation, antiaging, preserving, sterilizing, anti-inflammatory and the like; because the Beauveria sp. extract is produced by microorganism fermentation, the production of the Beauveria sp. extract is not influenced by environment and natural resources, and is easy to industrialize and automatize; the process method has low production cost, simple process, stable process, and high success rate and is easy to adjust and control; and the preparation method is suitable for investment of enterprises in various scales.

The present invention discloses a Gynostemma pentaphylla functional yoghurt product and a preparation method thereof. Lactobacillus plantarum HLX37 is added into fresh milk, 3wt.% Gynostemma pentaphyllum leach liquor, sucrose and pure water, and the yoghurt product is prepared by high-temperature fermentation process. The prepared yoghurt product can significantly reduce the damage of rat liver cells caused by high-fat diet, significantly reduce serum cholesterol and glucose levels in hyperlipidemia rats, and has a pharmacological effect in resisting lipid peroxidation in both inactivated and non-inactivated state; meanwhile, the yoghurt product can also significantly improve the immunity of rat intestine. The yoghurt product can be applied to mitigate or reduce the occurrence of high blood lipid, high blood pressure, high blood sugar symptoms for human beings, and can improve the immune function of human body at the same time, playing a good health-care role for human health.

The invention relates to the field of biotechnology, and particularly relates to an application of lactobacillus rhamnosus derived from longevity village in Bama of Guangxi in assisting in reducing blood fat. The animal experiment is carried out on the lactobacillus rhamnosus hsryfm1301 with the CGMCC No.8545, which is derived from the longevity village in Bama of Guangxi and has the capacity of externally reducing cholesterol and decomposing triglyceride; the function of assisting in reducing blood fat and the safety of the lactobacillus rhamnosus hsryfm1301 are evaluated. The result shows that afte hsryfm1301 is continuously fed to a rat for 7 days by gavage, the growing state of the rat is normal, the rat has smooth hair and active spirit, and the bacterial strain does not cause translocation and the like of liver sausages. The research on the functional characteristic of assisting in reducing blood fat in the experimental rat shows that the lactobacillus rhamnosus hsryfm1301 and acidified milk thereof are capable of reducing accumulation of fat in the liver of the rat and low density lipoprotein of serum, and the lactobacillus rhamnosus hsryfm1301 has the function of assisting in reducing blood fat.

The invention specifically relates to preparation of a microporous polymer coated hydrophilic resin and application thereof in glycopeptide enrichment. The preparation method includes: firstly preparing porous epoxy resin microspheres that have a particle size of 8-15microm and contain a plurality of epoxy functional groups on the surfaces, then adding m-phenylenediamine and isophthalaldehyde, andtaking acetic acid as the catalyst to prepare the hydrophilic resin coated with a layer of microporous organic polymer on the surface. The preparation conditions of the hydrophilic resin are simple and the reaction is mild. And finally, a standard glycoprotein (IgG) enzymolysis liquid is adopted as the sample to investigate the enrichment performance of hydrophilic resin to glycopeptide, and thehydrophilic resin can be further applied to glycoproteomics analysis in rat liver.

The invention relates to a preparation method of a ginger extract with detoxifying effect on exogenous carcinogens and a ginger extract product, and belongs to the technical field of deep processing of ginger. The preparation method comprises the following steps of: selecting and cleaning fresh ginger serving as a raw material, performing freeze drying, crushing, extracting with ethanol solution,and performing concentration to obtain ginger extract; performing ethyl acetate/ aqueous phase separation, collecting ethyl acetate layer, concentrating and drying, and thus obtaining the ethyl acetate extract; and finally, performing extraction by silica gel column chromatography, performing gradient elution by using ethyl acetate/ n-hexane system or the like, collecting elution components of 30to 70 percent ethyl acetate eluent, performing vacuum concentration, volatilizing the residual solvent by using a nitrogen blowing instrument, packing and sealing, and thus obtaining the ginger extract. The extract can remarkably induce the activity of quinone oxidoreductase (QR) in rat liver cancer Hepa1c1c7 cells, shows good potential of up-regulated II phase detoxifying enzyme, and can be usedfor developing low-toxicity efficient products such as cancer preventing agent, functional food and the like.

The invention discloses a differential proteomic analysis method using transcriptome sequencing and based on combination of iTRAQ and LC-MALDI. The method comprises the steps: (1) transcriptome sequencing is performed; (2) differential proteomic analysis is used for extracting the total protein fluid of livers of normal group rats and liver cancer group rats, the two groups are mixed respectively,proteins are precipitated and quantified by an acetone precipitation method, each group contains about 100 [mu]g of the total proteins, trypsin enzymolysis, reduction alkylation, iTRAQ labeling and the like are performed successively, and the process is performed by strictly following instructions of an iTRAQ kit; and (3) bioinformatics analysis is performed. A clinical sample is adopted for positioning and quantitative expression verification, an evidence of the clinical sample with clinical relevance is searched, clinical value is evaluated, and a new clue is provided for research of livercancer pathogenesis and a liver cancer mechanism. Liver cancer key molecules screened by the project can lay the research basis for exploration of liver cancer markers related to early detection, classification and prognosis evaluation, and selection of more effective and accurate liver cancer treatment target positions.

The invention belongs to the field of pharmacy and relates to a use of cyclocarya paliurus extract in preparation of a drug for preventing and treating non-alcoholic fatty liver disease. The cyclocarya paliurus extract can effectively reduce a degree of high fat diet-caused rat liver lipid accumulation and a triglyceride level and improve hepatic tissue and lung functions so that it is shown that the cyclocarya paliurus can substantially improve non-alcoholic fatty liver disease and can be used for preparation of a drug and a health product for preventing and treating non-alcoholic fatty liver disease. The cyclocarya paliurus extract widens an application range of a cyclocarya paliurus preparation in the medicine field and provides a novel choice for preventing and treating non-alcoholic fatty liver disease.

The invention provides an inducing and preparation method of rat liver S9. The inducing and preparation method comprises the following steps of (a) selecting a rat, injecting two types of inducing agents into an abdominal cavity by different types and dosages according to the weight of the rat, and determining the optimum inducing method; (b) killing the rat, removing residual blood in the livers under the sterile condition, and fetching out the livers; (c) under the sterile condition, adding a pre-freezing storage buffer liquid according to a certain liver-wet weight ratio, fully shearing, and equalizing pulp in an ice bath; (d) centrifuging a tissue liquid after pulp equalizing at low speed, collecting a supernatant and a precipitate, centrifuging the supernatant liquid at high speed, and collecting the supernatant liquid, so as to obtain the liver S9 for the first time; (e) adding the pre-freezing storage buffer liquid into the collected precipitate according to a certain ratio, fully grinding under the sterile and ice bath conditions, crushing cells by ultrasonic waves under different conditions, centrifuging at high speed, and collecting the supernatant liquid, so as to obtain the liver S9 again; (f) detecting the contents of protein and enzyme in the liver S9 by a BCA (bicinchoninic acid) method and a CO (carbon monoxide) reduction method under the different conditions. The inducing and preparation method of the rat liver S9 has the advantages that the output of liver S9 is increased, and the content of enzyme P450 is obviously increased.

A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.

The invention relates to a food composition with the effects of assisting blood fat reduction, weight loss and liver protection. The food composition is prepared from the following raw materials in parts by weight: 20-25 parts of fructus crataegi, 20-25 parts of lotus leaf, 10-16 parts of radix puerariae, 10-18 parts of green tea, 4-6 parts of fructus lycii, 4-8 parts of poria cocos, 2-4 parts offructus hippophae, 1-3 parts of celery powder, 1-3 parts of folium mori, 1-2 parts of konjac powder, 1 to 3 parts of fructus chaenomelis lagenariae, and 1 to 2 parts of rhizoma polygonati. The prepared food composition can significantly reduce the body weight, fat/body ratio, food utilization rate and blood triglyceride, total cholesterol and low density lipoprotein cholesterol levels in a high fat model rat in the dosage range of each component, also can reduce the liver index, alanine aminotransferase and alkaline phosphatase levels in the high-fat model rat, can significantly increase the relative abundance of bacteroides and decrease the relative abundance of firmicutes, and has the clear effects of assisting blood fat reduction, weight loss, liver protection and intestinal flora improvement.

The invention provides an antioxidant peptide in perilla seeds and an application thereof. The sequence of the antioxidant peptide is Tyr-Leu(YL). In vitro experiments show that the polypeptide can effectively remove ABTS, superoxide anions and various reactive oxide species (ORAC). Meanwhile, the peptide can effectively inhibit linoleic acid and rat liver lipid peroxidation. Cell experiments prove that the peptide is safe to cells and has obvious inhibiting effects on oxidative damages of the cell HepG-2. The antioxidant peptide has the characteristics of simple structure, safety, strong antioxidation activity, and the like, can serve as an excellent substitute for existing synthetic antioxidants and has important value for development and application of novel antioxidant health care products and food additives.